PTGDR — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Domitroban (SCHEMBL98345)	0.86	18/20
Domitroban (SCHEMBL98346)	0.86	18/20
Domitroban (SCHEMBL124474)	0.85	18/20
Ramatroban (SCHEMBL29030)	1.00	6/20
Ramatroban (SCHEMBL29031)	1.00	6/20
SCHEMBL138678	0.71	5/20
SCHEMBL139890	0.68	5/20
SCHEMBL150210	0.67	5/20
SCHEMBL150731	0.67	5/20
SCHEMBL141704	0.66	5/20
SCHEMBL142884	0.66	5/20
SCHEMBL137868	0.65	5/20
SCHEMBL142814	0.65	5/20
SCHEMBL137965	0.65	5/20
SCHEMBL150280	0.64	5/20
SCHEMBL135513	0.64	5/20
SCHEMBL150112	0.61	5/20
SCHEMBL142815	0.61	5/20
SCHEMBL149844	0.60	5/20
SCHEMBL138780	0.60	5/20

Clinical trials — most relevant to PTGDR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pharmacogenomics of Antiplatelet Response - I	PHASE4	COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite	PHASE2/PHASE3	WITHDRAWN
European Celecoxib Trial in Primary Breast Cancer	PHASE3	COMPLETED
Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial	PHASE3	UNKNOWN
Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial	PHASE3	UNKNOWN
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes	PHASE3	UNKNOWN
Triamcinolone Versus Methylprednisolone in Transversus Abdominis Plane Block	PHASE2/PHASE3	COMPLETED
Addition of Aspirin to Standard of Care in Oral Cancer	PHASE2/PHASE3	COMPLETED
Montelukast for Early Life Wheezing	PHASE2/PHASE3	COMPLETED
Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors	PHASE1/PHASE2	COMPLETED
Effect of OC459 on the Response to Rhinovirus Challenge in Asthma	PHASE2	COMPLETED
Adjunctive Celecoxib in Childhood-onset OCD Study	PHASE2	UNKNOWN
Prostaglandin Inhibition for Emphysema	PHASE2	COMPLETED
Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention	PHASE2	COMPLETED
Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine	PHASE2	WITHDRAWN
DHA For The Treatment of Pediatric Concussion Related to Sports Injury	PHASE1	COMPLETED
Study About Patients Using Copper Intrauterine Device	nan	COMPLETED
Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein	nan	COMPLETED
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B	nan	COMPLETED
Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates	nan	RECRUITING
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A	nan	ACTIVE_NOT_RECRUITING
Maresin-1 and Resolvin-D1 Levels and Disease Activity in Ulcerative Colitis	nan	COMPLETED
Positron Emission Tomography (PET) to Study Brain Signaling	nan	COMPLETED
The Efficacy of Two Types of Acupuncture on Autonomic Nervous Activity and Quality of Life in Women With Dysmenorrhea.	nan	UNKNOWN
Forced Oscillometry in Infants With Bronchopulmonary Dysplasia	nan	RECRUITING
Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture	nan	UNKNOWN
Prostaglandin and Cannabinoid Receptors in EoE	nan	COMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
PET Imaging of DHA Metabolism	nan	COMPLETED
Characterization of the Inhibitory Effects of Fevipiprant (QAW039) on Activation of Eosinophils and ILC2 Cells by Prostaglandin D2 Metabolites	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PTGDR binder may also engage these)

Protein	Name	Similarity
Q9R261	—	0.994	Q9R261 →
O35932	—	0.993	O35932 →
A5D7K8	—	0.992	A5D7K8 →
P70263	—	0.992	P70263 →
Q95125	—	0.984	Q95125 →
P56486	—	0.981	P56486 →
P30987	—	0.981	P30987 →
P34978	—	0.981	P34978 →
P79393	—	0.980	P79393 →
PTGIR	Prostacyclin receptor	0.980	landscape →
TBXA2R	Thromboxane A2 receptor	0.979	landscape →
Q62928	—	0.979	Q62928 →
Q62053	—	0.978	Q62053 →
PTGER2	Prostaglandin E2 receptor EP2 subtype	0.978	landscape →
P43252	—	0.976	P43252 →
P43253	—	0.976	P43253 →
P30557	—	0.969	P30557 →
Q9XT82	—	0.968	Q9XT82 →
P34980	—	0.966	P34980 →
P50131	—	0.966	P50131 →
PTGER3	Prostaglandin E2 receptor EP3 subtype	0.964	landscape →
P70597	—	0.963	P70597 →
P46069	—	0.963	P46069 →
P35375	—	0.961	P35375 →
P47752	—	0.959	P47752 →
P43117	—	0.958	P43117 →
S1PR2	Sphingosine 1-phosphate receptor 2	0.957	landscape →
P34979	—	0.952	P34979 →
P52592	—	0.952	P52592 →
PTGFR	Prostaglandin F2-alpha receptor	0.952	landscape →